Editor's Note Hospitals achieved a substantial reduction in mortality risk for surgical inpatients between 2019 and 2024, even as patients grew sicker and stayed longer, according to a report released August 5 by the American Hospital Association (AHA) and Vizient. In the first quarter of 2024, hospitalized surgical patients were…
Editor's Note According to results from a randomized trial, titled KEYNOTE-689, adding pembrolizumab (Keytruda) to surgery and standard adjuvant therapy significantly prolongs event-free survival (EFS) in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC), MedPage Today April 28 reports. Experts are calling the findings a major…